172 related articles for article (PubMed ID: 36722625)
21. An Excellent Response to Tofacitinib in a Pediatric Alopecia Patient: A Case Report and Review.
Brown L; Skopit S
J Drugs Dermatol; 2018 Aug; 17(8):914-917. PubMed ID: 30124734
[TBL] [Abstract][Full Text] [Related]
22. Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study.
Ricar J; Cetkovska P; Hordinsky M; Ricarova R
Dermatol Ther; 2022 Jun; 35(6):e15438. PubMed ID: 35278027
[TBL] [Abstract][Full Text] [Related]
23. Clinical profile and impact on quality of life: seven years experience with patients of alopecia areata.
Al-Mutairi N; Eldin ON
Indian J Dermatol Venereol Leprol; 2011; 77(4):489-93. PubMed ID: 21727697
[TBL] [Abstract][Full Text] [Related]
24. Burden of Illness in Alopecia Areata: A Cross-Sectional Online Survey Study.
Mesinkovska N; King B; Mirmirani P; Ko J; Cassella J
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S62-S68. PubMed ID: 33099390
[TBL] [Abstract][Full Text] [Related]
25. Congenital alopecia areata.
Lenane P; Pope E; Krafchik B
J Am Acad Dermatol; 2005 Feb; 52(2 Suppl 1):8-11. PubMed ID: 15692503
[TBL] [Abstract][Full Text] [Related]
26. The value of dermoscopy in diagnosing eyebrow loss in patients with alopecia areata and frontal fibrosing alopecia.
Waśkiel-Burnat A; Rakowska A; Kurzeja M; Czuwara J; Sikora M; Olszewska M; Rudnicka L
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):213-219. PubMed ID: 30290016
[TBL] [Abstract][Full Text] [Related]
27. Alopecia Areata: An Update on Treatment Options for Children.
Peloquin L; Castelo-Soccio L
Paediatr Drugs; 2017 Oct; 19(5):411-422. PubMed ID: 28551734
[TBL] [Abstract][Full Text] [Related]
28. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
[TBL] [Abstract][Full Text] [Related]
29. The efficacy of latanoprost in the treatment of alopecia areata of eyelashes and eyebrows.
Faghihi G; Andalib F; Asilian A
Eur J Dermatol; 2009; 19(6):586-7. PubMed ID: 19620039
[TBL] [Abstract][Full Text] [Related]
30. Isolated eyebrow and eyelash trichotillomania mimicking alopecia areata.
Radmanesh M; Shafiei S; Naderi AH
Int J Dermatol; 2006 May; 45(5):557-60. PubMed ID: 16700791
[TBL] [Abstract][Full Text] [Related]
31. Comparison of quality of life in patients with androgenetic alopecia and alopecia areata.
Gonul M; Cemil BC; Ayvaz HH; Cankurtaran E; Ergin C; Gurel MS
An Bras Dermatol; 2018; 93(5):651-658. PubMed ID: 30156613
[TBL] [Abstract][Full Text] [Related]
32. Acquired causes of eyebrow and eyelash loss: A review and approach to diagnosis and treatment.
Mumford BP; Eisman S; Yip L
Australas J Dermatol; 2023 Feb; 64(1):28-40. PubMed ID: 36320026
[TBL] [Abstract][Full Text] [Related]
33. Methotrexate for the treatment of pediatric alopecia areata.
Landis ET; Pichardo-Geisinger RO
J Dermatolog Treat; 2018 Mar; 29(2):145-148. PubMed ID: 28627278
[TBL] [Abstract][Full Text] [Related]
34. The Invisible Impact of a Visible Disease: Psychosocial Impact of Alopecia Areata.
Mesinkovska N; Craiglow B; Ball SG; Morrow P; Smith SG; Pierce E; Shapiro J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1503-1515. PubMed ID: 37289409
[TBL] [Abstract][Full Text] [Related]
35. Alteration in hair texture following regrowth in alopecia areata: a case report.
Valins W; Vega J; Amini S; Woolery-Lloyd H; Schachner L
Arch Dermatol; 2011 Nov; 147(11):1297-9. PubMed ID: 21768446
[TBL] [Abstract][Full Text] [Related]
36. High Relapse Rates Despite Early Intervention with Intravenous Methylprednisolone Pulse Therapy for Severe Childhood Alopecia Areata.
Smith A; Trüeb RM; Theiler M; Hauser V; Weibel L
Pediatr Dermatol; 2015; 32(4):481-7. PubMed ID: 25872976
[TBL] [Abstract][Full Text] [Related]
37. Eyebrows Are Important in the Treatment of Alopecia Areata.
Liu LY; King BA; Ko JM
J Investig Dermatol Symp Proc; 2020 Nov; 20(1):S37-S40. PubMed ID: 33099382
[TBL] [Abstract][Full Text] [Related]
38. Clobetasol propionate, 0.05%, vs hydrocortisone, 1%, for alopecia areata in children: a randomized clinical trial.
Lenane P; Macarthur C; Parkin PC; Krafchik B; DeGroot J; Khambalia A; Pope E
JAMA Dermatol; 2014 Jan; 150(1):47-50. PubMed ID: 24226568
[TBL] [Abstract][Full Text] [Related]
39. Quality of life measurement in alopecia areata. Position statement of the European Academy of Dermatology and Venereology Task Force on Quality of Life and Patient Oriented Outcomes.
Chernyshov PV; Tomas-Aragones L; Finlay AY; Manolache L; Marron SE; Sampogna F; Spillekom-van Koulil S; Pustisek N; Suru A; Evers AWM; Salavastru C; Svensson A; Abeni D; Blome C; Poot F; Jemec GBE; Linder D; Augustin M; Bewley A; Salek SS; Szepietowski JC
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1614-1621. PubMed ID: 34107093
[TBL] [Abstract][Full Text] [Related]
40. 308-nm excimer laser for the treatment of alopecia areata in children.
Al-Mutairi N
Pediatr Dermatol; 2009; 26(5):547-50. PubMed ID: 19840308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
